Cancer

Lunit, Labcorp Partner on AI-Powered Digital Pathology Research

The collaboration combines Labcorp's clinical expertise with Lunit's AI algorithms to analyze tumor microenvironments and enhance biomarker discovery.

Cancer

Watchmaker Genomics Launches New Tech Enabling Simultaneous Detection of Methylation and Genetic Variants

TAPS+ chemistry preserves DNA integrity in challenging samples including FFPE tissue and circulating tumor DNA.

Cancer

Biodesix Expands Bio-Rad Partnership for Droplet Digital PCR Assay Development

The agreement focuses on clinical validation of ESR1 mutation detection assay for advanced breast cancer testing using ddPCR technology.

Proscia Expands AI Capabilities to Support Skin Pathology Evaluation

Oct 15, 2025 | Melanoma

New skin tissue analysis tools aim to address diagnostic challenges in one of pathology’s most diverse specialties.

Circulogene Launches Tissue-Based Genomic Profiling Assay for Solid Tumors

Oct 10, 2025 | Cancer

OncoGenDx analyzes 335 DNA genes and 72 RNA genes using next-generation sequencing technology to support treatment decisions.

Genetic Test Now Available to Predict Radiation Therapy Side Effects in Prostate Cancer

Oct 2, 2025 | Prostate

PROSTOX ultra identifies patients at higher risk of developing late genitourinary toxicity from stereotactic body radiation therapy.

Pancreatic Cancer Study Reaches 10,000 Participants Worldwide

Oct 2, 2025 | Pancreatic

The PRECEDE Consortium doubles its enrollment target to 20,000 as it builds a dataset for early detection tool development.

Prospective Trial Shows PAM50 Biomarker Predicts Hormone Therapy Benefit in Prostate Cancer

Oct 1, 2025 | Prostate

Study finds molecular signature identifies which men with recurrent disease respond to apalutamide plus salvage radiation therapy.

Lab Introduces Self-Collected HPV Test to Enhance Privacy and Access

Oct 1, 2025 | Cervical (HPV)

The new testing option detects 14 high-risk HPV strains without requiring pelvic examination, targeting patients 30 and older with no previous abnormal screenings.

AI-Powered Blood Test Shows Promise for Early Lung Cancer Detection

Oct 1, 2025 | Lung Cancer

A new blood-based test that combines four protein markers with artificial intelligence has demonstrated potential for early lung cancer detection in a multicenter retrospective study.

AI-Driven Platform Aims to Bring Personalized Cancer Treatment to More Patients

Sep 29, 2025 | Cancer

First Ascent Biomedical is validating a live-cell testing platform that screens over 150 FDA-approved therapies against a patient’s tumor, generating individualized treatment insights in about 10 days.

Quest Diagnostics to Expand Blood-Based Colorectal Cancer Screening Access

Sep 26, 2025 | Colorectal

The company is collaborating with Guardant Health to make Guardant’s Shield test available through Quest’s nationwide network of provider clients and patient service centers.

Why Closing Lung Cancer’s Diagnostic Gap Will Require New Lab Strategies

Sep 25, 2025 | Lung Cancer

On World Lung Day, Reveal Dx board member Mat Brevard discusses why current diagnostic tools fall short—and how new approaches could improve accuracy and outcomes.

UnitedHealthcare Covers CNS Cancer Cerebrospinal Fluid Assay

Sep 25, 2025 | Unknown Origin & Other Cancer Types

The laboratory-developed test is used to detect and monitor metastatic central nervous system cancer.

Large Clinical Trial to Assess Nasal Swab Test for Guiding Lung Cancer Care

Sep 24, 2025 | Lung Cancer

The 2,400-patient study evaluates the Percepta Nasal Swab test’s ability to guide management decisions for patients with lung nodules.

FDA Authorizes KMT2A FISH Test as Companion Diagnostic for Acute Leukemia Therapy

Sep 23, 2025 | Leukemia

The breakapart probe detects gene rearrangements in acute leukemia patients to identify candidates for menin inhibitor therapy.

Clinical Study to Evaluate ctDNA Test for Guiding Lung Cancer Treatment

Sep 22, 2025 | Lung Cancer

Haystack Oncology and Rutgers Cancer Institute collaborate on phase II trial examining minimal residual disease testing in stage II/III NSCLC patients.

Investigational AI Tool Cuts Acute Leukemia Diagnosis Time to Two Hours

Sep 22, 2025 | Leukemia

MARLIN uses DNA methylation patterns and machine learning to classify leukemia subtypes, potentially accelerating treatment decisions.

Category: Cancer

Cancer

Cancer

Cancer